Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for vitiligo: experimental drug aims to bring back skin color

NCT ID NCT07431177

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 6 times

Summary

This study tests an experimental drug called GIA632 in 210 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the drug can safely restore skin color and to find the best dose for future studies. Participants will receive either the drug or a placebo, and neither they nor their doctors will know which one they are getting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study * Male or female as assigned at birth ≥ 18 years of age at the time of screening * Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator * Non-segmental vitiligo, as assessed at screening, as * ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5 * ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60 Exclusion Criteria: * Individuals unable or unwilling to follow the study procedures and/or to complete the study-related questionnaires * Presence of segmental or mixed vitiligo, or other skin comorbidities that may interfere with study assessments (e.g., hypopigmented mycosis fungoides, genetic diseases with pigmentary aberrations \[such as piebaldism, Waardenburg, etc.\], chemical- or druginduced leukoderma, etc.) * Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors * Individual who previously attempted or completed depigmentation therapy for NSV * Use of prohibited medication \& treatments. Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized vitiligo vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-segmental vitiligo

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    76 sites in 12 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ACRC Trials

    RECRUITING

    Plano, Texas, 75024, United States

  • Austin Inst for Clinical Research

    RECRUITING

    Pflugerville, Texas, 78660, United States

  • Bellaire Dermatology Associates

    RECRUITING

    Bellaire, Texas, 77401, United States

  • Cahaba Derm and skin hlth ctr 27

    RECRUITING

    Birmingham, Alabama, 35244, United States

  • Center for Clinical Studies

    RECRUITING

    Houston, Texas, 77030, United States

  • Clinical Trials Research Institute

    RECRUITING

    Thousand Oaks, California, 91320, United States

    Contact Email: •••••@•••••

  • Dawes Fretzin Clinical Rea Group

    RECRUITING

    Indianapolis, Indiana, 46256, United States

  • Encore Medical Research

    RECRUITING

    Hollywood, Florida, 33024, United States

  • Equity Medical

    RECRUITING

    The Bronx, New York, 10455, United States

  • First OC Dermatology

    RECRUITING

    Fountain Valley, California, 92708, United States

  • Global Clinical Professionals

    RECRUITING

    St. Petersburg, Florida, 33714, United States

  • Hamzavi Dermatology

    RECRUITING

    Fort Gratiot, Michigan, 48059, United States

  • International Clinical Research Tennessee LCC

    RECRUITING

    Murfreesboro, Tennessee, 37130, United States

  • Las Vegas Dermatology

    RECRUITING

    Las Vegas, Nevada, 89144, United States

  • Mayo Clinic Jacksonville

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • MedDerm Associates

    RECRUITING

    San Diego, California, 92103, United States

  • Miami Derm and Laser Institute

    RECRUITING

    Miami, Florida, 33173, United States

  • Novartis Investigative Site

    RECRUITING

    Buenos Aires, Buenos Aires, C1425DKG, Argentina

  • Novartis Investigative Site

    RECRUITING

    Caba, Buenos Aires, C1119ACN, Argentina

  • Novartis Investigative Site

    RECRUITING

    Rosario, Santa Fe Province, 2000, Argentina

  • Novartis Investigative Site

    RECRUITING

    Sydney, New South Wales, 2010, Australia

  • Novartis Investigative Site

    RECRUITING

    Waitara, New South Wales, 2077, Australia

  • Novartis Investigative Site

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Novartis Investigative Site

    RECRUITING

    Calgary, Alberta, T2J 7E1, Canada

  • Novartis Investigative Site

    RECRUITING

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Novartis Investigative Site

    RECRUITING

    Mississauga, Ontario, L4Y 4C5, Canada

  • Novartis Investigative Site

    RECRUITING

    Newmarket, Ontario, L3Y 5G8, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M3H 5Y8, Canada

  • Novartis Investigative Site

    RECRUITING

    Québec, Quebec, G1V 4X7, Canada

  • Novartis Investigative Site

    RECRUITING

    Guangzhou, Guangdong, 510091, China

  • Novartis Investigative Site

    RECRUITING

    Wuhan, Hubei, 430022, China

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100050, China

  • Novartis Investigative Site

    RECRUITING

    Shanghai, 200040, China

  • Novartis Investigative Site

    RECRUITING

    Bordeaux, 33075, France

  • Novartis Investigative Site

    RECRUITING

    Brest, 29609, France

  • Novartis Investigative Site

    RECRUITING

    Créteil, 94010, France

  • Novartis Investigative Site

    RECRUITING

    Nice, 06202, France

  • Novartis Investigative Site

    RECRUITING

    Reims, 51100, France

  • Novartis Investigative Site

    RECRUITING

    Rouen, 76031, France

  • Novartis Investigative Site

    RECRUITING

    Toulouse, 31400, France

  • Novartis Investigative Site

    RECRUITING

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    RECRUITING

    Bad Bentheim, 48455, Germany

  • Novartis Investigative Site

    RECRUITING

    Bielefeld, 33647, Germany

  • Novartis Investigative Site

    RECRUITING

    Hamburg, 20354, Germany

  • Novartis Investigative Site

    RECRUITING

    Hanover, 30625, Germany

  • Novartis Investigative Site

    RECRUITING

    Lübeck, 23538, Germany

  • Novartis Investigative Site

    RECRUITING

    Münster, 48149, Germany

  • Novartis Investigative Site

    RECRUITING

    Tübingen, 72076, Germany

  • Novartis Investigative Site

    RECRUITING

    Ahmedabad, Gujarat, 380016, India

  • Novartis Investigative Site

    RECRUITING

    Bangalore, Karnataka, 560074, India

  • Novartis Investigative Site

    RECRUITING

    Belagavi, Karnataka, 590010, India

  • Novartis Investigative Site

    RECRUITING

    Mysore, Karnataka, 570001, India

  • Novartis Investigative Site

    RECRUITING

    Nashik, Maharashtra, 422101, India

  • Novartis Investigative Site

    RECRUITING

    Ancona, AN, 60020, Italy

  • Novartis Investigative Site

    RECRUITING

    Cona, FE, 44124, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20122, Italy

  • Novartis Investigative Site

    RECRUITING

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 4578510, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 4678602, Japan

  • Novartis Investigative Site

    RECRUITING

    Urayasu, Chiba, 2790021, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 1600023, Japan

  • Novartis Investigative Site

    RECRUITING

    Kofu, Yamanashi, 4008506, Japan

  • Novartis Investigative Site

    RECRUITING

    Niigata, 9518520, Japan

  • Novartis Investigative Site

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Santiago de Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    RECRUITING

    Córdoba, 14004, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28006, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Novartis Investigative Site

    RECRUITING

    Pontevedra, 36003, Spain

  • Novartis Investigative Site

    RECRUITING

    Seville, 41009, Spain

  • Oregon Medical Research Center

    RECRUITING

    Portland, Oregon, 97223, United States

  • Revival Research Institute

    RECRUITING

    Troy, Michigan, 48084, United States

  • Skin Specialists PC

    RECRUITING

    Omaha, Nebraska, 68144, United States

  • Virginia Clinical Research

    RECRUITING

    Norfolk, Virginia, 23507, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.